[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563493":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":38,"responsibleParty":54,"collaborators":11,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":11,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":11,"overallStatus":75,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Sequence A","EXPERIMENTAL",null,[13,14],"Drug: DA-5221_01","Drug: DA-5221_01-R1 + DA-5221_01-R2",{"label":16,"type":10,"description":11,"interventionNames":17},"Experimental: Sequence B",[13,14],[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","DA-5221_01","single dose administration (DA-5221\\_01 one tablet once a day)",[9,16],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DA-5221_01-R1 + DA-5221_01-R2","single dose administration (DA-5221\\_01-R1 one tablet once a day + DA-5221\\_01-R2 one tablet once a day)",[9,16],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Sung","CONTACT","+82-02-920-8369","jhsung@donga.co.kr",{"name":35,"role":31,"phone":36,"phoneExt":11,"email":37},"Jung","+82-02-920-8361","jungjy@donga.co.kr",[39],{"facility":40,"status":11,"city":41,"state":42,"zip":43,"country":42,"countryCode":11,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Bumin Hospital","Seoul","South Korea","07590",{"type":45,"coordinates":46},"Point",[47,48],126.9784,37.566,{"lat":48,"lon":47},[51],{"name":52,"role":31,"phone":11,"phoneExt":11,"email":53},"TaeGon Hong, Ph.D","tghong@bumin.co.kr",{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100563493","phase-1-pharmacokinetics-and-safety-profiles-after-administration-of-da-522101-and-co-administration-of-522101-r1-and-da-522101-r2-in-healthy-adult-volunteers-100563493",false,"NCT06616883","Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult Volunteers","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Cross-over Study to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Single Administration of DA-5221_01 and Concomitant Administration of DA-5221_01-R1 and DA-5221_01-R2 Under Fasting Conditions in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy volunteers\n* BMI between 18 and 30 kg\u002Fm2\n* Body weight: Male≥50kg, Female≥45kg\n* Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study\n\nExclusion Criteria:\n\n* Subjects with clinically significant medical history\n* Subjects with history of drug abuse or addicted",true,"ALL","19 Years",{"count":67,"type":68},44,"ESTIMATED","INTERVENTIONAL",[71],"PHASE1","Pharmacokinetics and Safety Profiles After Administration of DA-5221\\_01 and Co-administration of 5221\\_01-R1 and DA-5221\\_01-R2 in Healthy Adult Volunteers",[74],"Healthy","NOT_YET_RECRUITING","2024-09-25",{"date":78,"type":79},"2024-09-27","ACTUAL",{"date":81,"type":68},"2024-09-30",{"date":83,"type":68},"2024-11-18",{"name":5,"class":6},1]